STROBE Statement—checklist of items that should be included in reports of observational studies

Section/item	Item No	Recommendation	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Line 31 (pg 2)	"Background" of Abstract
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Lines 27-53 (pg 2-3)	Abstract (Whole)
Introduction				
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	Lines 57-104 (pg 4-5)	Introduction (Whole)
Objectives	3	State specific objectives, including any prespecified hypotheses	Lines 78-104 (pg 5)	Introduction Paragraphs
Methods				
Study design	4	Present key elements of study design early in the paper	Lines 96-103; 108-122 (pg	"Data Source and
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Lines 108-122 (pg 6)	"Data Source and Selection Critera"
Participants	6	(a) ***Cohort study***—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up ***Case-control study***—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls ***Cross-sectional study***—Give the eligibility criteria, and the sources and methods of selection of participants	Lines 108-130 (pg 6)	"Data Source and Selection Criteria" (including) Supplemental Appendix Figure S1, " Variables of Interest"
		(b) ***Cohort study***—For matched studies, give matching criteria and number of exposed and unexposed ***Case-control study***—For matched studies, give matching criteria and the number of controls per case	Lines 152-153 (pg 7)	Describes Propensity Score Matching method
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Lines 124-138 (pg 6-7)	"Variables of interest" in Methods
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Lines 124-160 (pg 6-7)	"Variables of interest" and "Statistical analysis"
Bias	9	Describe any efforts to address potential sources of bias	Lines 131-154 (pg 7)	"Variables of interest"
Study size	10	Explain how the study size was arrived at	Lines 108-122 (pg 6)	"Data Source and
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Lines 123-160 (pg 6-7)	"Variables of Interest" and "Statistical Analysis"

Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Lines 131-156 (pg 6-7)	"Variables of interest"
		(b) Describe any methods used to examine subgroups and interactions	Lines 131-156 (pg 7)	"Statistical Analysis"
		(c) Explain how missing data were addressed	Lines 108-122 (pg 6)	"Data Source and
		(d) ***Cohort study***—If applicable, explain how loss to follow-up was addressed ***Case-control study***—If applicable, explain how matching of cases and controls was addressed ***Cross-sectional study***—If applicable, describe analytical methods taking account of sampling strategy	N/A Loss to follow-up not relevant with this national database and patients filtered out anyways	N/A
		(e) Describe any sensitivity analyses	N/A--none performed	N/A
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Lines 163-172 (pg 8)	Supplemental Figure S1and "Patient characteristics" in Results
		(b) Give reasons for non-participation at each stage	Line 122 (Reference to	Supplemental Figure S1
		(c) Consider use of a flow diagram	Line 122 (Reference to	Supplemental Figure S1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Lines 163-172 (pg 8)	"Patient Characteristics"
		(b) Indicate number of participants with missing data for each variable of interest	Lines 173-179; 503-505	"Survival" in Results
		(c) ***Cohort study***—Summarise follow-up time (eg, average and total amount)	Lines 128-130; 164-177	Supplemental Figure S1
Outcome data	15*	***Cohort study***—Report numbers of outcome events or summary measures over time	Lines 164-179 (pg 8)	"Patient Characteristics"
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	N/A--not a case-control	N/A
		Cross-sectional study—Report numbers of outcome events or summary measures	N/A--not cross sectional	N/A
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Lines 174-186 (pg 8-9)	"Survival"
		(b) Report category boundaries when continuous variables were categorized	Lines 174-199 (pg 8-9)	"Survival"
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A-RR not used here	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Lines 180-199 (pg 9)	"Survival"
Discussion				
Key results	18	Summarise key results with reference to study objectives	Lines 201-282 (pgs9-10)	Discussion as a whole but
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Lines 298-314 (pg 13)	"Stengths and Limitations" Paragraph 2 (in Discussion)

Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Lines 201-314 (pg 9-13)	Discussion as a whole
Generalisability	21	Discuss the generalisability (external validity) of the study results	Lines 285-297 (pg 13)	"Stengths and Limitations"
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Lines 327, 339-341 (pg 15)	"Funding"

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

Article information: https://dx.doi.org/10.21037/tlcr-22-682
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.